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Abstract
Background: Vascular endothelial growth factor (VEGF), platelet derived endothelial cell growth factor/thymidine 
phosphorylase (PD-ECGF/TP) and leptin are known as potent angiogenic factors The objective of the study was to 
evaluate these angiogenic factors VEGF, PD-ECGF/TP and leptin in children with congenital heart disease (CHD) and 
the factors that lead to angiogenesis in such cases.
Methods: Sixty CHD children were studied and divided into two groups (n = 30); cyanotic-CHD (C-CHD) and 
acyanotic-CHD (A-CHD). Twenty five healthy children were included as controls.
Results: Significantly higher serum levels of VEGF, PD-ECGF/TP activity and leptin were detected in patients with CHD, 
particularly in patients with C-CHD. CHD patients with SpO2 <90%, pulmonary hypertension (PH), severe pulmonary 
stenosis (PS), detectable collaterals, cardiomegaly and/or heart failure showed significantly higher levels of these 
factors than those with higher SpO2 or those without these findings.
Conclusion: Hypoxia, PH and PS are important factors that lead to harmful angiogenesis. However, angiogenesis could 
be essential in some cases of CHD as coarctation of aorta to enhance renal perfusion. This may provide new ways for 
therapeutic strategies aiming at reducing or promoting angiogenesis in CHD to improve patient's outcome.
Background
Angiogenesis or neovascularization by capillary sprout-
ing from preexisting vessels is a major physiological event
that occurs for example in embryogenesis, wound healing
and menstrual cycle. It is also, implicated in certain path-
ological conditions such as atherosclerosis, diabetic retin-
opathy, tumor growth, psoriasis and myocardial
ischemia. This could occur through the interplay of the
endothelial cells, angiogenic mediators, cytokines,
growth factors, and adhesion molecules [1].
Children with CHD may experience the development
of abnormal vascular channels that become a source of
significant morbidity and mortality. However, no entity
responsible for these abnormalities has been identified
yet [2]. Therefore, such vessels are needed to be closed
either before or after the cardiac operation [3]. On the
other hand, cases with CHD as coarctation of aorta,
enlargement of preexisting or formation of new collater-
als is very characteristic and essential for enhancement of
renal perfusion as hypertension is not due to mechanical
obstruction alone, but almost certainly involves renal
mechanisms [4].
Angiogenic growth factors are so called because of
their varying ability to induce the proliferation of various
cells in vitro, which contribute to the process of angio-
genesis in vivo [5]. Vascular endothelial growth factor
(VEGF), platelet derived endothelial cell growth factor/
thymidine phosphorylase (PD-ECGF/TP) and leptin are
known as potent angiogenic factors [5-7]. VEGF is a basic
45 kDa disulfide linked dimeric glycoprotein that binds
heparin and is structurally related to platelet derived
growth factors. The whole VEGF family consists of at
least five members (VEGF A-B-C-D-E) whose effects are
mediated via three VEGF receptors (VEGF R-1, VEGF R-
2 and VEGF R-3). Through alternate exon splicing of
VEGF gene, different mRNA are encoded producing five
biologically active proteins (VEGF121, VEGF145, VEGF165,
VEGF189 and VEGF206) [5]. PD-ECGF/TP is identical to
TP (EC-2-4-2-4). PD-ECGF/TP is a 47 kDa non glycosy-
lated single chain polypeptide that stimulates chemotaxis
for endothelial cells in vitro and of angiogenesis in vivo
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[8]. Despite a wealth of data linking PD-ECGF and angio-
genic pathology, the molecular mechanisms underlying
this link have thus for remained obscure [6]. Leptin, the
16 kDa non-glcosylated polypeptide product of the obese
gene, is an adipocyte-derived cytokine that regulates food
intake and energy homeostasis. Leptin is also, defined as
a potent angiogenic factor [9,10]. Understanding of the
role of these angiogenic factors in CHD could be impor-
tant in medical or surgical management of such cases [4].
Aim of work: The present study was designed to evalu-
ate the angiogenic factors (VEGF, PD-ECGF/TP and lep-
tin) in children with CHD and the factors that lead to
angiogenesis in such cases.
Methods
The study included 60 children with CHD diagnosed
clinically and by echocardiography. They were attending
Cardiology Unite at Children University Hospital, Assiut.
They were divided into two groups; C-CHD (n = 30) (16
boys and 14 girls). Their mean age was 3.38 ± 0.78 years
and mean weight 10.2 ± 3.2 Kg. A-CHD group (n = 30)
(22 boys and 8 girls). Their mean age was 3.20 ± 2.12
years and mean weight 11.46 ± 4.82 Kg. The diseases of
C-CHD were 14 Tetralogy of Fallot (TOF), 9 transposi-
tion of great arteries (TGA), 7 double outlet right ventri-
cle (DORV). The A-CHD had 11 ventricular septal defect
(VSD), 8 pulmonary stenosis (PS), 5 coarctation of aorta,
3 patent ductus arteriosus (PDA) and 3 atrial septa defect
(ASD). A control group of 25 apparently healthy children
(15 boys and 10 girls), with mean age 3.48 ± 2.31 years
and mean weight 13.5 ± 4.7 Kg were included in the
study. All patients were subjected to full history taking,
clinical and echocardiographic examination. Diagnostic
cardiac catheter as preoperative evaluative procedure was
done in 15 cases {10 TOF, 2 coarctation of aorta and 3
VSD with pulmonary hypertension (PH)}. Severe PS was
considered when the pressure gradient (PG) between the
right ventricle and the pulmonary artery is >60 mmHg
[11]. PH is defined as mean pulmonary artery pressure
>25 mmHg at rest or >30 mmHg during exercise [11].
Severe coarctation of aorta is diagnosed when the PG
between the pre and post the coarctation segment was
>60 mmHg [11]. Arterial blood oxygen saturation (SpO2)
was measured by pulse oxymeter. Patients who were
operated either with palliative or complete surgical cor-
rection of CHD were excluded from the study as hemo-
dynamics and angiogenesis could be altered
postoperatively. According to age, weight, hemoglobin
level and SpO2 level, CHD patients were divided into {<3
ys (n = 39) and >3 ys (n = 21)}, {<10 kg (n = 34) and >10
Kg (n = 26)}, {<10 g./dl (n = 32) and >10 g./dl (n = 28)},
{<90% (n = 35) and >90% (n = 25)} for comparison. The
clinical, laboratory, echocardiographic and catheter crite-
ria of the studied CHD patients were presented in tables 1
and 2. Most of the studied patients will undergo total cor-
rective or palliative surgery according to their conditions
and will be evaluated postoperatively by echocardiogra-
phy.
All parents of subjects gave written informed consent
prior to the study. The study was approved by the Com-
mittee of Ethics in Medical Research at Assiut University,
Faculty of Medicine.
Five ml of blood sample were collected by vein punc-
ture under complete aseptic condition. Samples were
Table 1: Clinical, laboratory, echocardiographic and catheter criteria of the studied patients with CHD
Patients groups
Studied parameters
C-CHD (n = 30) A-CHD (n = 30)
Heart failure (n = 18/60) 12 6
Cardiomegaly (n = 25/60) 14 11
SpO2 (%) 80.6 ± 7.3 97.1 ± 0.5
Hemoglobin (g./dl) 16.78 ± 2.5 10.0 ± 2.1
PH (n = 12/60) 8 4
Severe PS (n = 21/60) 16 5
collaterals by echo (n = 11/60) 7 4
collaterals by catheter (n = 8/19) 6 2El-Melegy and Mohamed Italian Journal of Pediatrics 2010, 36:32
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allowed to clot for 30 minutes and centrifuged at 1000 g
for 10 minutes at 4°C. Serum was removed and stored at -
20°C in aliquots till time of assay. Serum VEGF levels
w e r e  m e a s u r e d  w i t h  Q a u a n t i k i n e  V E G F 165 ELISA kite
Catalog number DVEOO (R & D system, Minneapolis,
MN) according to method of He et al. [12]. Levels of
activity of serum PDECGF/TP were determined by spec-
trophotometric measurement of the free thymine base
produced as a result of the enzyme catalytic reaction [13].
Serum levels of leptin were measured with DRG leptin
ELISA Catalog number EIA-2395, supplied by DRG
instruments GmbH, Germany [14].
Statistical analysis
Data were analyzed using statistical package (SPSS Ver-
sion 11). The results were presented as mean ± SD. Data
comparisons were performed using two tailed unpaired
student t-test, and Pearson correlation coefficient was
used for correlations. A value of p < 0.05 was considered
to be significant.
Results
Significantly higher mean serum levels of the studied bio-
indices (VEGF, PD-ECGF/TP activity and leptin) were
found in patients with CHD in comparison to those of the
controls. Patients with C-CHD showed significantly
higher levels of the studied bioindices in comparison to
those of the A-CHD (P < 0.01 each) {Table 3}. The mean
l e v e l s  o f  V E G F  w e r e  s i g n i f i c a n t l y  h i g h e r  i n  C - C H D
patients aged more than 3 years than those aged less than
3 years (P < 0.01). Both C-CHD and A-CHD patients
weighed more than 10 Kg showed significantly higher
mean serum leptin levels than those weighed less than 10
Kg (P < 0.01). Mean serum levels of VEGF and PD-ECGF/
TP were significantly higher in C-CHD patients with
hemoglobin levels more than 10 g./dl than those of
patients with hemoglobin levels less than 10 gm/dl. Sig-
nificantly higher mean serum levels of the studied bioin-
dices were observed in patients with CHD having SpO2 %
less than 90% than those with SpO2 % more than 90%
{Table 4}. CHD patients with PH, those with severe PS
and with collaterals showed significantly higher mean
serum levels of VEGF, PD-ECGF/TP and leptin than
those without PH, with mild PS and without collaterals.
Also, significantly higher mean serum levels of VEGF
were observed in C-CHD patients with heart failure and
those with cardiomegaly in comparison to those without
(P < 0.05) {Table 5, 6}. Table 7 shows significant positive
correlations in patients with CHD between VEGF and
each of PD-ECGF/TP, leptin, age, hemoglobin, pulmo-
nary pressure and PS. and between PD-ECGF/TP and
leptin (p < 0.001). Also, significant positive correlations
were observed between leptin and each of PD-ECGF/TP
and weight. However, a significant negative correlation
was observed between VEGF and SpO2 %.
Table 2: Clinical, laboratory, echocardiographic and catheter criteria in different types of CHD
Patients groups C-CHD (n = 30) A-CHD (n = 30)
Studied 
Parameters
TOF
(n = 14)
TGA
(n = 9)
DORV
(n = 7)
VSD
(n = 11)
PS
(n = 8)
Aortic coarct
(n = 5)
PDA
(n = 3)
ASD
(n = 3)
Heart failure (n = 18/60) 4 5 3 5 - 1 - -
Cardiomegaly (n = 25/60) 4 4 4 7 - 1 3 2
SpO2 (%) 83 ± 3.6 80 ± 2.1 82.6 ± 5.4 97 ± 1.3 96 ± 2.2 96.2 ± 3.1 97.1 ± 4.8 94 ± 3.5
Hemoglobin (g./dl) 15 ± 3.3 16.2 ± 2 16.9 ± 4.3 10.5 ± 2 10 ± 3.2 10.4 ± 3.6 11.9 ± 1.8 10.8 ± 0.9
PH (n = 12/60) - 5 3 4 - - - -
Severe PS (n = 21/60) 11 2 3 - 5 - - -
Collaterals by echo (n = 11/60) 5 1 1 - 2 2 - -
Collaterals by catheter (n = 8/19) 6 Not done Not done - Not done 2 Not done Not doneEl-Melegy and Mohamed Italian Journal of Pediatrics 2010, 36:32
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Discussion
Abnormal blood vessel proliferation often occurs in
patients with CHD and this may represent a form of
anomalous angiogenesis, especially in the lungs or myo-
cardium [15].
The present study demonstrated significant higher
mean serum levels of VEGF, PD-ECGF/TP activity and
leptin in children with CHD particularly the cyanotic
group (Table 3).
Angiogenesis normally occurs at variable rates in differ-
ent organs, because it depends on the tissue regeneration.
That response is amplified under conditions that results
in cellular hypoxia [2]. Hypoxia (decreased SpO2) that
leads to polycythemia with increased hemoglobin level is
a strong stimulus for angiogenesis. Hu et al. [15] stated
that preoperative serum VEGF level elevation was
because of hypoxia in the C-CHD, but then became lower
after surgery because of the elimination of hypoxia. In
contrast, the serum VEGF level significantly increased
postoperatively in patients with A-CHD, possibly from
myocardial ischemia during cardiopulmonary bypass.
Nevertheless, in the C-CHD hypoxia is still the main
cause of the high serum VEGF levels rather than myocar-
dial ischemia. The response to hypoxia is primarily medi-
ated by the transcription factor hypoxia-inducible factor-
1 (HIF-1) which leads to the induction of a variety of
adaptive gene products including VEGF [16]. Further
mechanisms leading to hypoxia-induced increase of
VEGF production may be related to the often associated
features of hypoxia such as tissue damage, necrosis and
apoptosis. These events may therefore trigger the release
of cytokines and other chemical mediators from the cells
of the surrounding tissue, initiating a cascade of events
leading to the production of VEGF [5]. These findings
could explain the observations of the present study that
significant higher mean serum levels of VEGF were
detected in C-CHD patients with higher hemoglobin
level >10 g./dl than those with lower hemoglobin <10 g./
dl and in C-CHD and A-CHD patients with lower SpO2
level <90% than those with higher SpO2 level >90% (Table
4) and the significant positive correlation between the
levels of VEGF and hemoglobin and significant negative
correlation between VEGF and SpO2 (Table 7). These
findings are in agreement with those of Himeno et al. [3]
and Suda et al. [17]. However, Ootaki et al [2] found no
significant correlation between VEGF level and SpO2 or
RBCs. They attributed this to the fact that VEGF is classi-
fied into subgroups and some types of VEGF are not
affected by hypoxia (VEGF-B and C).
In the present study, C-CHD patients with older age >3
ys showed a significantly higher levels of VEGF than
younger age <3 ys (Table 4). There were significant posi-
tive correlations between VEGF and age (Table 7). These
findings are in accordance with those of Himeno et al. [3]
who reported that VEGF showed significant age depen-
dence. Hu et al. [15] stated that the myocardial microves-
sel formation increased with age and this could be
attributed to the older the age the longer the duration of
angiogenesis formation in C-CHD. Accordingly, they sug-
gested that early surgical intervention may improve the
outcome of CHD. However, the study of Rivard et al. [18]
reported that the expression of VEGF was impaired in old
animals compared with younger ones.
C-CHD patients with heart failure and those with car-
diomegaly showed significant higher mean serum levels
of VEGF than patients without (Table 5). Early PH in
Table 3: Serum levels of VEGF, PD-ECGF/TP activity and leptin in patients groups and controls
Biomarkers VEGF (pg/ml) PD-ECGF (U/ml) Leptin (ng/ml)
Patients groups mean ± SD Range mean ± SD Range mean ± SD Range
Cyanotic (n = 30) 
(I)
410.83 ± 102.79 195-600 31 ± 8.22 15-50 41.96 ± 11.05 20-60
Acyanotic (n = 30) 
(II)
308.66 ± 85.74
a†
180-450 21.16 ± 6.7
a†
12-35 32.93 ± 9.53
a†
15-48
Controls (n = 25) 
(III)
141.4 ± 55.38
a* b*
65-250 14.96 ± 4.37
a† b‡
9-23 8.88 ± 2.03
a* b*
5-12.5
a: Groups II, III versus I
b: Group III versus II
*: p < 0.001
†: p < 0.01
‡: p < 0.05El-Melegy and Mohamed Italian Journal of Pediatrics 2010, 36:32
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heart failure is characterized by altered vasoreactivity
with overexpression of VEGF [19]. Izumiya et al. [20]
reported that VEGF is required to maintain myocardial
capillary density and that reduction in vascular bed is
associated with the transition from compensated hyper-
trophy to heart failure. Moreover, Tirziu et al. [21] stated
that the enhancement of angiogenesis in failing heart is to
improve myocardial function. They reported that an
increase in size of vascular bed in normal heart leads to
increased cardiac mass and hypertrophy paralleled by
increased cardiac performance.
It has been shown that TP activity is critical for the
angiogenic activity of PD-ECGF/TP. TP hydrolyzes thy-
midine to 2-deoxy-D-ribose-1-phosphate (2-DDR1P) and
thymine. In turn 2 DDR1P is dephosphorylated to 2-
deoxy-D-ribose (2-DDR). These ribose sugar metabolites
are strong reducing sugars that generate oxygen radical
species during the early stages of protein glycation. The
induced oxidative stress has been implicated in the
release of angiogenic factor (ex. VEGF) [6,22]. In addi-
tion, 2-DDR could possibly exert a chemokinetic effect by
integrating into the metabolic machinery of endothelial
cell generating energy that can serve towards endothelial
cell migration which has been suggested to be essential
for angiogenesis [22]. Characterizing the angiogenic
p a t h w a y s  d o w n s t r e a m  o f  T P  a c t i v i t y  w i l l  a l l o w  u s  t o
uncouple angiogenesis from thymidine phosphorylysis.
This is of clinical relevance to block TP-induced angio-
genesis downstream of TP activity which could prevent
the induction of blood vessel growth [6].
The present study revealed that mean serum activity
levels of PD-ECGF/TP activity were significantly higher
in CHD patients with low SpO 2 (Table 4). This finding
could be attributed to hypoxia. Griffiths and Dachs [23]
reported that the presence of PD-ECGF/TP is a common
feature in all diseases characterized by hypoxia and aber-
rant angiogenesis. They added that the mechanism of
hypoxic induction of PD-ECGF/TP may be similar to that
of VEGF[22,23]. These findings could explain the signifi-
cant positive correlation between VEGF and PD-ECGF/
Table 4: Serum levels of VEGF, PD-ECGF/TP activity and leptin in patients groups in relation to age, weight, hemoglobin 
and SpO2 levels.
Biomarkers VEGF (pg/ml) PD-ECGF (U/ml) Leptin (ng/ml)
Patients 
groups
C-CHD (n = 30) A-CHD (n = 30) C-CHD (n = 30) A-CHD (n = 30) C-CHD (n = 30) A-CHD (n = 30)
<3 ys (n = 39) 265 ± 100 296 ± 79 29 ± 7 20 ± 10.2 39 ± 12 32 ± 10
Age
>3 ys (n = 21) 574 ± 92* 310 ± 91§ 34 ± 9.3§ 27 ± 6§ 43 ± 6.5§ 33.6 ± 5.9§
<10 Kg (n = 34) 400 ± 96 306 ± 74 28.6 ± 7.8 25 ± 4.9 22 ± 4.9 20.9 ± 8.9
Weight
>10 Kg (n = 26) 413 ± 78§ 327 ± 36§ 33 ± 6.4§ 30 ± 6.7§ 43 ± 10† 45.3 ± 9†
<10 gm/dl (n = 32) 275 ± 102 300.5 ± 90 18.4 ± 6.4 21.2 ± 7.3 41 ± 7.9 31 ± 4.8
Hemogl
>10 gm/dl (n = 28) 567 ± 95* 313.2 ± 76§ 39 ± 9.6† 24.9 ± 6§ 43.8 ± 8§ 33.7 ± 5.6§
<90% (n = 35) 582 ± 98 408 ± 59.2 48.3 ± 7.8 33 ± 5.4 49 ± 12 46.8 ± 9.5
SpO2
>90% (n = 25) 206 ± 39* 210 ± 65.4* 27 ± 9.6† 18 ± 6.9† 27.8 ± 10.8‡ 22 ± 6.2 ‡
*: p < 0.001
†: p < 0.01
‡: p < 0.05
§: not significantEl-Melegy and Mohamed Italian Journal of Pediatrics 2010, 36:32
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TP observed in CHD patients in the present study (Table
7).
The angiogenic function of leptin demonstrates that
this endocrine hormone acts as a paracrine growth factor
for the vascular system [24]. In addition, leptin also, acts
as an indirect angiogenic factor. Interestingly, leptin mod-
ulates VEGF-induced vascular activity by synergistically
promoting neovascularization in vivo [24]. The study of
suganami et al. [7] reported that leptin stimulates neovas-
cularization possibly through the upregulation of VEGF
in retinal endothelial cells. This synergism is by upregula-
tion of VEGF mRNA expression via activation of Janus-
tyrosine kinase-signal transducer and activator of tran-
scripition (Jak-STAT) [10]. These findings could explain
the observed significant positive correlation between
VEGF and leptin in the studied CHD patients (Table 7).
Hypoxia which is a well-known stimulator of leptin syn-
thesis and secretion [25], it markedly enhances the
expression of leptin and VEGF as well as stimulating HIF-
1α which transactivate the leptin gene promoter [9]. This
could explain the present finding that significant higher
serum leptin levels were observed in CHD patients with
lower SpO2 (Table 4). In the present study, significant
h i g h e r  s e r u m  l e p t i n  l e v e l s  w e r e  o b s e r v e d  i n  C H D
patients with body weight >10 kg than those patients <10
kg (Table 4). Also, significant positive correlation was
observed between leptin and body weight (Table 7).
Numerous studies have revealed that leptin concentra-
tions are significantly elevated in obese subjects in pro-
portion to the degree of adiposity. The mechanism by
which the increase in body fat is translated into increase
in serum leptin appears to involve induction of Ob gene
expression [14]. However, the study of Hallioglu et al. [26]
reported that the leptin regulating axis is intact in cyan-
otic patients and does not contribute to cachexia of CHD.
Significant higher serum levels of VEGF, PD-ECGF/TP
activity and leptin were observed in CHD patients with
PH than patients without (Table 5). Also, there was a sig-
nificant positive correlation between VEGF and level of
pulmonary pressure (Table 7). This is in agreement with
that of Lam et al. [27] who detected increased expression
of VEGF in the pulmonary artery of rats with high pul-
monary flow. Mata-Greenwood et al. [28] suggested that
increased pulmonary blood flow upregulates expression
of VEGF and its receptors, and this may be important in
development of the vascular remodeling in the pulmo-
nary artery exposed to high flow and pressure. The char-
acteristic vascular changes include intimal hyperplasia/
Table 5: Serum levels of VEGF, PD-ECGF/TP activity and leptin in patients groups in relation to PH, severity of PS, presence 
or absence of heart failure and cardiomegaly
Biomarkers VEGF (pg/ml) PD-ECGF (U/ml) Leptin (ng/ml)
Studied 
parameters
Cyanotic 
(n = 30)
Acyanotic 
(n = 30)
Cyanotic 
(n = 30)
Acyanotic 
(n = 30)
Cyanotic 
(n = 30)
Acyanotic 
(n = 30)
With (n = 12) 589 ± 89 395 ± 78 39.6 ± 4.4 30 ± 6.0 59.5 ± 6.0 44.6 ± 6.1
PH
Without (n = 48) 276 ± 92* 187 ± 85* 22.2 ± 7.3† 19.9 ± 5.7† 30.2 ± 11† 23.8 ± 5.1†
Severe (n = 21) 478 ± 74 384 ± 62 47.3 ± 6.6 33 ± 8.9 53.6 ± 8.4 41 ± 6.5
PS
mild (n = 3) 199 ± 52* 220 ± 77† 27 ± 8.9† 17.9 ± 7.4† 30 ± 13.3† 22.8 ± 7.9†
With (n = 18) 519 ± 79 3854 ± 88 29 ± 6.4 32.2 ± 5.8 52 ± 7.4 41 ± 2.9
Heart 
Without (n = 42) 476 ± 68‡ 87 ± 74§ 22 ± 7.0§ 29 ± 8.5§ 44 ± 10.6§ 33 ± 9.5§
With (n = 25) 379 ± 55 292 ± 67 39 ± 4.0 32.3 ± 6.0 43 ± 9.9 43 ± 8.2
Cardiomega
Without (n = 35) 294 ± 95‡ 201 ± 77§ 27 ± 6.1§ 30 ± 4.9§ 42 ± 12§ 36 ± 7.0§
*: p < 0.001
†: p < 0.01
‡: p < 0.05
§: not significantEl-Melegy and Mohamed Italian Journal of Pediatrics 2010, 36:32
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fibrosis, medial hypertrophy, extensive extracellular
matrix modulation, and, in more severe cases, the forma-
tion of plexiform lesion [29]. These changes lead to
decreased compliance of pulmonary vasculature and
changes in vasoreactivity of pulmonary arteries [30].
Significant higher mean serum levels of VEGF, PD-
ECGF/TP activity and leptin were observed in CHD with
collaterals than those without (Table 6). These finding
agree with those of previous studies [2,15,31]. Starnes et
al. [31] reported that VEGF appears to be systemically
Table 7: Correlation coefficient (r) between the studied parameters in patients with CHD
Studied parameters VEGF
(pg/ml)
PD-ECGF/TP
(U/ml)
Leptin
(ng/ml)
PD-ECGF/TP (U/ml) r = 0.847* - -
Leptin (ng/ml) r = 0.833* r = 0.769* -
Age (years) r = 0.562 ‡ r = 0.266§ r = 0.334§
Weight (Kg) r = 0.206§ r = 0.260§ r = 0.448 ‡
Hemoglobin (g./dl) r = 0.799* r = 0.260§ r = 0.206§
SpO2 (%) r = -0.856* r = 0.320§ r = 0.268§
Pulmonary pressure (mmHg) r = 0.799* r = 0.260§ r = 0.288§
Severity of PS (mmHg) r = 0.879* r = 0.433 ‡ r = 0.527 ‡
Severity of aortic coarctation (mmHg) r = 0.904* r = 0.662 † r = 0.531 ‡
Heart failure r = 0.266§ r = 0.280§ r = 0.302§
Cardiomegaly r = 0.205§ r = 0.240§ r = 0.300§
*: p < 0.001
†: p < 0.01
‡: p < 0.05
§: not significant
Table 6: Serum levels of VEGF, PD-ECGF/TP activity and leptin in the studied patients in relation to presence or absence of 
collaterals detected by echocardiography and/or catheter
Biomarkers VEGF PD-ECGF  Leptin 
Collaterals (pg/ml) (U/ml) (ng/ml)
Collaterals (n = 11) 490.3 ± 77 43.2 ± 7.8 48.6 ± 8.7
Echo (n = 60)
No (n = 49) 232.7 ± 80.2* 21.0 ± 9.4† 29.0 ± 8.8†
Collaterals (n = 8) 512.0 ± 80.3 46.1 ± 9.3 51.5 ± 7.32
Catheter (n = 19)
No (n = 11) 266.0 ± 92.0* 27.0 ± 10.5† 26.4 ± 9.9†
*: p < 0.001
†: p < 0.01El-Melegy and Mohamed Italian Journal of Pediatrics 2010, 36:32
http://www.ijponline.net/content/36/1/32
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elevated in patients with chronic cyanosis, and may con-
tribute to the formation of extensive collateral vessels.
Ootaki et al. [2] reported that, even without major abnor-
mal vessels, patients with C-CHD frequently have high
amounts of collateral flow by numerous small collaterals.
These secondarily developed systemic pulmonary collat-
erals might relate to VEGF levels. These findings may
suggest that the use of gene therapy of VEGF inhibitors
might represent a way to limit collateral development [3].
Also, significant higher serum levels of VEGF, PD-ECGF/
TP activity and leptin were observed in CHD patients
with severe PS than patients with mild PS (Table 5). Aor-
topulmonary collateral arteries associated with pulmo-
nary atresia or severe PS may lead to several problems,
including significant left to right shunting and pulmonary
"steal" from systemic flow during cardiopulmonary
bypass. On the other hand, the maintenance of collaterals
that extend in cases of severe coarctation of aorta to sup-
ply the post stenotic ischemic tissues especially kidneys is
very essential for their perfusion. Higher blood pressure
in the capillaries of the aorta proximal to the area of
obstruction leads to remodeling of the thoracic arteries
and of collateral vessels. Promoting angiogenesis in such
conditions could be very beneficial to provide better
blood supply and to reverse ischemia [4].
Study limitations
The present study has its own limitations: the broad vari-
ation in circulatory dynamics within the studied groups
with various CHD. Variability of the underlying hemody-
namics and anatomy may make consistent analysis diffi-
cult. Another limitation was small number of the studied
CHD patients.
Conclusions
The present study represents an attempt to identify fac-
tors that may have an impact on CHD. Hypoxia, PH and
PS are important factors that lead harmful angiogenesis
and many surgical hazards. On the other hand, angiogen-
esis could be essential in cases of CHD associated with
peripheral ischemia as in coarctaion of aorta to enhance
renal perfusion. These findings may aid in understanding
of the control mechanisms of angiogenesis in these
patients. This may provide new ways of research for ther-
apeutic strategies aiming at reducing or promoting angio-
genesis in CHD in order to improve patient's outcome.
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